All In Biotech

Drug Trial Radar · NCT00644358

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)

A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Sep 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

616

Actual

Start

Dec 31, 2007

Primary completion

May 31, 2009

Study completion May 31, 2009

Sponsor

Lead sponsor
Forest LaboratoriesAbbVie (ABBV)
Sponsor type
Industry
First posted
Mar 26, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open label 52-week clinical trial is designed to assess the safety and tolerability of vilazodone and to analyze genetic markers of response to vilazodone in adult patients diagnosed with MDD. This study will enroll approximately 600 patients.

Conditions

  • Major Depressive Disorder

Interventions

  • vilazodoneDrug

    titration to 40 milligrams (mg) every day (qd) for 1 year

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From first dose of study medication and up to 30 days after the last dose of study medication (Up to 13 months)

Locations

38 sites in 1 country. Site status is shown where the registry gives one.

  • Collaborative Neuroscience Network, Inc.

    Garden Grove, California

  • Affiliated Research Institute

    San Diego, California

  • Collaborative Neuroscience Network, Inc

    Torrance, California

  • Pacific Clinical Research

    Upland, California

  • Radiant Research

    Denver, Colorado

  • CNS Clinical Research Group

    Coral Springs, Florida

  • Gulfcoast Clinical Research

    Fort Myers, Florida

  • Sarkis Clinical Trials

    Gainesville, Florida

  • Clinical Neuroscience Solutions, Inc

    Jacksonville, Florida

  • Florida Clinical Research Center, LLC

    Lady Lake, Florida

  • Clinical Neuroscience Solutions, PA

    Orlando, Florida

  • Stedman Clinical Trials

    Tampa, Florida

  • Carman Research

    Smyrna, Georgia

  • Chicago Research Center

    Chicago, Illinois

  • Capstone Clinical Research

    Libertyville, Illinois

  • Davis Clinic

    Indianapolis, Indiana

  • Vince and Associates Clinical Research

    Overland Park, Kansas

  • Capital Clinical Research Associates

    Rockville, Maryland

  • Summit Research Network

    Farmington, Michigan

  • Radiant Research

    St Louis, Missouri

  • Radiant Research

    Las Vegas, Nevada

  • Bioscience Research, LLC

    Mount Kisco, New York

  • Eastside Comprehensive Medical Center

    New York, New York

  • The Medical Research Network, LLC

    New York, New York

  • North Coast Clinical Trials

    Beachwood, Ohio

  • Patient Priority Clinical Sites, LLC

    Cincinnati, Ohio

  • North Star Medical Research, LLC

    Middleburg Heights, Ohio

  • IPS Research Company

    Oklahoma City, Oklahoma

  • Paramount Clinical Research

    Bridgeville, Pennsylvania

  • Introspect of Buxmont

    Colmar, Pennsylvania

  • Suburban Research Associates

    Media, Pennsylvania

  • Clinical Neuroscience Solutions

    Memphis, Tennessee

  • FutureSearch Trials

    Austin, Texas

  • FutureSearch Trials

    Dallas, Texas

  • Croft Group Research Center

    San Antonio, Texas

  • Neuropsychiatric Associates

    Woodstock, Vermont

  • Neuroscience, Inc.

    Herndon, Virginia

  • Dominion Clinical Research

    Midlothian, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.